Update shared on 28 Nov 2025
Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates.
Analyst Commentary
Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.
Bullish Takeaways- Revenue for the recent quarter significantly exceeded expectations, showcasing strong demand and solidifying confidence in RxSight’s execution capabilities.
- Analysts believe that current revenue projections for 2026 are reasonable, reducing concerns about overstated future growth expectations.
- The increase in the price target reflects a more favorable view of the company's near-term performance and its ability to deliver consistent growth.
- Continued positive momentum and outperformance versus Wall Street estimates underscore the potential for the company to deliver further upside surprises in future periods.
- Despite the price target raise, analysts maintain a Hold rating, which indicates some lingering uncertainty around valuation at current levels.
- Some caution remains regarding sustainability of elevated revenue growth, particularly as future earnings targets become more ambitious.
- Analysts are mindful that further upside may rely on exceeding already robust market expectations, leaving limited room for underperformance.
- Certain unknowns relating to market expansion and competitive positioning could impact long-term execution and growth.
What's in the News
- RxSight provided earnings guidance for the fourth quarter of 2025, projecting revenue between $23 million and $28 million. (Key Developments)
- The company raised and narrowed its 2025 revenue guidance to a range of $125 million to $130 million. This is up from the previous range of $120 million to $130 million. (Key Developments)
- A class action lawsuit has been filed against RxSight and certain officers. The suit alleges the company made misleading statements regarding adoption challenges and sales performance, and failed to meet its own financial guidance for 2025. (Key Developments)
Valuation Changes
- Fair Value remains unchanged at $9.67 per share. This reflects continued stability in overall valuation estimates.
- Discount Rate has fallen slightly from 7.76% to 7.75%, indicating a modest reduction in perceived investment risk.
- Revenue Growth expectation is virtually unchanged and remains steady at approximately 3.35%.
- Net Profit Margin has edged down fractionally from 13.39% to 13.38%, suggesting stable profitability projections.
- Future P/E ratio has risen marginally from 24.77x to 24.78x, implying minor adjustments in forward earnings expectations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.